Evidence map›Paper›PMID 33367272›Full record

ArticleAnnals of pancreatic cancer2020

Quantitative metric for assessment of pancreatic ductal adenocarcinoma treatment response in T1-weighted gadolinium-enhanced magnetic resonance imaging.

Joy Liau, Srinivasan Vedantham, Hani M Babiker, Travis McGlothin, Diego R Martin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of pancreatic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Joy LiauDepartment of Radiology, University of California at San Diego, San Diego, CA, USA.
Srinivasan VedanthamDepartments of Medical Imaging and Biomedical Engineering, University of Arizona, Tucson, AZ, USA.
Hani M BabikerEarly Phase Clinical Trials Program, University of Arizona Cancer Center, Tucson, AZ, USA.
Travis McGlothinDepartment of Medical Imaging, University of Arizona, Tucson, AZ, USA.
Diego R MartinDepartment of Radiology and the Translational Imaging Institute, Houston Methodist Hospital, Houston, TX, USA.
Banner - University Medical Center Tucson · USMethodist Hospital · USUniversity of Arizona · USUniversity of California, San Diego · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
NCI NIH HHS P30 CA023074
6 · The paper itself

Abstract

backgroundWe theoretically derived a new quantitative metric reflecting the product of T1 signal intensity and contrast media concentration (

methodsOut of 264 initially identified patients, a final total of 35 patients with PDA were included in a retrospective study of responders (n=24) and non-responders (n=11), which used changes in cancer antigen 19-9 (CA 19-9) and tumor size as reference standards.

resultsIn the treatment responder group,

conclusions

Indexed as

magnetic resonance imaging (MRI)Pancreatic cancerT1treatment response

Identifiers

PMID33367272
PMCPMC7755136
OpenAlexW3107858353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.